Our Company
About Us
Leadership
Scientific Advisory Board
Contact Us
LB-102 Publications
Clinical Programs
Investors
About Schizophrenia
How do antipsychotics work?
Publications
News
Presentations
SEC Filings
News
LB Pharmaceuticals Press Releases
July 19, 2022
LB Announces Publication of Phase 1 Clinical Study of LB-102
December 7, 2021
LB Announces Presentation of Full Results of Dopamine Receptor Occupancy Study of LB-102 at the 2021 ACNP Conference
October 4, 2021
LB Pharmaceuticals Presents Results of Dopamine Receptor Occupancy Studies of LB-102 at ECNP Conference
April 26, 2021
LB Pharmaceuticals To Participate in the B. Riley Securities’ Neuroscience Conference
February 2, 2021
LB Pharmaceuticals Announces the Initiation of Patient Dosing in Open Label Phase 1b Imaging Study of LB-102
September 25, 2020
LB Pharmaceuticals Inc Secures $10.0 million in Additional Financing
September 14, 2020
LB Pharmaceuticals Inc Announces Results of LB-102 First-in-Human Clinical Study
September 2, 2020
LB Pharmaceuticals Inc Announces the Hiring of Dr. Anna Eramo as Chief Medical Officer
January 22, 2020
LB Pharmaceuticals Inc Announces the Initiation of Patient Dosing in a First-in-Human Phase 1 Study of LB-102, a Novel Benzamide for the Treatment of Schizophrenia
August 15, 2019
LB Pharmaceuticals Inc Announces the Publication of Its First Peer-Reviewed Manuscript
July 8, 2019
LB Pharmaceuticals Inc Appoints Robert R. Ruffolo, Jr., Ph.D. to its Board of Directors
March 4, 2019
LB Pharmaceuticals Inc Secures $8.4 Million in Series A Financing
January 1, 2019
LB Pharmaceuticals Inc Announces Issuance of U.S. Patent Covering N-Methyl Amisulpride for the Treatment of Psychiatric Disorders
Want to stay in the loop?
Join our mailing list
First Name
Last Name
Company
Email address:
Leave this field empty if you're human:
Our Company
About Us
Leadership
Scientific Advisory Board
Contact Us
LB-102 Publications
Clinical Programs
Investors
About Schizophrenia
How do antipsychotics work?
Publications
News
Presentations
SEC Filings